Table 1.

Patient characteristics.

Characteristics	n (%)
Median age (range)	68 (48–94)
Gleason score (n = 42)
≤7	15 (35.7)
8–10	27 (64.3)
Initial diagnosis (n = 42)
Localized	21 (50.0)
Metastatic	21 (50.0)
ECOG PS (n = 44)
0 (fully active)	11 (25.0)
1 (restricted)	33 (75.0)
Metastatic sites (n = 43)
2	3 (7.0)
≥3	40 (93.0)
Site of disease (n = 43)
Viscerala	20 (46.5)
Liver	12 (60.0)
Lung	9 (45.0)
Other	3 (15.0)
Non-visceral	23 (53.5)
Type of progression at trial entry (n = 44)
PSA-only	4 (9.1)
Radiographic (by RECIST/PCWG3) ± PSA	40 (90.9)
Baseline Ki-67 expression by IHC (n = 31)
Low (<20%)	8 (25.8)
High (≥20%)	23 (74.2)
Prior therapy	n (%)
Type of prior therapyb (n = 44)
Chemotherapy	44 (100)
Docetaxel	44 (100)
Cabazitaxel	40 (90.9)
Carboplatin	2 (4.5)
Paclitaxel	1 (2.3)
Novel hormonal agent	44 (100)
1	37 (84.1)
2c	7 (15.9)
Abiraterone	24 (54.5)
Enzalutamide	24 (54.5)
Apalutamide	2 (4.5)
Darolutamide	1 (2.3)
Radiopharmaceuticals	2 (4.5)
Radium-223	1 (2.3)
177Lu-PSMA	1 (2.3)
Immunotherapy	6 (13.6)
Pembrolizumab	3 (6.8)
Atezolizumab	1 (2.3)
Durvalumab	1 (2.3)
Ipilimumab	1 (2.3)
Nivolumab	1 (2.3)
Number of prior therapies for mCRPC (n = 44)
≤2	19 (43.2)
≥3d	25 (56.8)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration–resistant prostate cancer; PCWG3, Prostate Cancer Clinical Trials Working Group 3; RECIST, Response Evaluation Criteria in Solid Tumors.

^aFour patients had both liver and lung lesions.

^bPatients may have received multiple prior therapies in any setting, including mHSPC, nmCRPC, or mCRPC.

^cOne patient received the two NHAs in combination.

^dThree patients had four prior therapies for mCRPC.